Tej Sheth

Tej Sheth

Auto-generated profile, based on publicly available information

Tej Sheth

Division of Cardiology, Hamilton Health Sciences and McMaster University, Canada (T.S., J.V., M.S.).

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2025 in JMIR Research Protocols
Verified
Journal Article
Open access
JPJeremy Petch
Jeremy Petch
JBJuan Pablo Tabja Bortesi
Juan Pablo Tabja Bortesi
TSTej Sheth
Tej Sheth
MNMadhu Natarajan
Madhu Natarajan
NPNatalia Pinilla-Echeverri
Natalia Pinilla-Echeverri
JSJon-David Schwalm
Jon-David Schwalm
Background: Invasive coronary angiography (ICA) is the gold standard in the diagnosis of coronary artery disease (CAD). Being invasive, it carries rare but serious risks including myocardial infarction, stroke, major bleeding, and death. A large proportion of elective outpatients undergoing ICA have nonobstructive CAD, highlighting the suboptimal use of this test. Coronary computed tomographic angiography (CCTA) is a noninvasive option that provides similar information with less risk and is recommended as a first-line test for patients with low-to-intermediate risk of CAD. Leveraging artificial intelligence (AI) to appropriately direct patients to ICA or CCTA based on the predicted probability of disease may improve the efficiency and safety of diagnostic pathways. Objective: he CarDIA-AI (Coronary computed tomographic angiography to optimize the Diagnostic yield of Invasive Angiography for low-risk patients screened with Artificial Intelligence) study aims to evaluate whether AI-based risk assessment for obstructive CAD implemented within a centralized triage process can optimize the use of ICA in outpatients referred for nonurgent ICA. Methods: CarDIA-AI is a pragmatic, open-label, superior randomized controlled trial involving 2 Canadian cardiac centers. A total of 252 adults referred for elective outpatient ICA will be randomized 1:1 to usual care (directly proceeding to ICA) or to triage using an AI-based decision support tool. The AI-based decision support tool was developed using referral information from over 37,000 patients and uses a light gradient boosting machine model to predict the probability of obstructive CAD based on 42 clinically relevant predictors, including patient referral information, demographic characteristics, risk factors, and medical history. Participants in the intervention arm will have their ICA referral forms and medical charts reviewed, and select details entered into the decision support tool, which recommends CCTA or ICA based on the patient’s predicted probability of obstructive CAD. All patients will receive the selected imaging modality within 6 weeks of referral and will be subsequently followed for 90 days. The primary outcome is the proportion of normal or nonobstructive CAD diagnosed via ICA and will be assessed using a 2-sided z test to compare the patients referred for cardiac investigation with normal or nonobstructive CAD diagnosed through ICA between the intervention and control groups. Secondary outcomes include the number of angiograms avoided and the diagnostic yield of ICA. Results: Recruitment began on January 9, 2025, and is expected to conclude in mid to late 2025. As of April 14, 2025, we have enrolled 81 participants. Data analysis will begin once data collection is completed. We expect to submit the results for publication in 2026. Conclusions: CarDIA-AI will be the first randomized controlled trial using AI to optimize patient selection for CCTA versus ICA, potentially improving diagnostic efficiency, avoiding unnecessary complications of ICA, and improving health care resource usage. Trial Registration: ClinicalTrials.gov NCT06648239; https://clinicaltrials.gov/study/NCT06648239/ International Registered Report Identifier (IRRID): DERR1-10.2196/71726

3 June 2026 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
MMMehdi Madanchi
Mehdi Madanchi
NPNatalia Pinilla-Echeverri
Natalia Pinilla-Echeverri
DWDavid A. Wood
David A. Wood
TSTej Sheth
Tej Sheth
RSRobert F. Storey
Robert F. Storey
SMShamir R. Mehta
Shamir R. Mehta
BACKGROUND: Complete revascularization is superior to culprit lesion–only percutaneous coronary intervention (PCI) in reducing ischemic events in patients with ST-segment–elevation myocardial infarction and multivessel disease. However, the relationship between the extent of revascularization and the benefits of a complete revascularization strategy remains unclear. The aim of this substudy of the COMPLETE trial was to evaluate how the degree of anatomic completeness of revascularization, measured by the core laboratory-derived modified residual SYNTAX score (R′SS), relates to major cardiovascular events. METHODS: We conducted an exploratory post hoc analysis of the COMPLETE trial (n=3738), stratifying patients randomized in the complete revascularization group based on the R′SS assessed after staged nonculprit lesion–PCI. Complete revascularization was defined by an R′SS=0, whereas incomplete revascularization was defined by an R′SS>0. A stratified Cox proportional hazards model was used, with the culprit-only PCI arm designated as the reference group for comparison. The first coprimary outcome was a composite of cardiovascular death or new myocardial infarction. The second coprimary outcome was a composite of cardiovascular death, new myocardial infarction, or ischemia-driven revascularization. RESULTS: Among patients randomized to a complete revascularization strategy, 90% achieved complete revascularization (R′SS=0), whereas 10% did not (R′SS>0). In patients with R′SS=0, the first coprimary outcome occurred less frequently (6.6%) compared with those randomized to the culprit lesion–only PCI strategy (10.7%; adjusted hazard ratio, 0.61 [95% CI, 0.47–0.78]). Among patients with an R′SS>0, the first coprimary outcome was similar (10.7%) to those in the culprit lesion–only PCI group (10.7%; adjusted hazard ratio, 1.01 [95% CI, 0.61–1.67]). A similar result was observed for the second coprimary outcome. CONCLUSIONS: This exploratory analysis of the COMPLETE trial suggests that the benefit of a complete revascularization strategy in patients with ST-segment–elevation myocardial infarction and multivessel disease may be related to the extent of anatomic completeness of revascularization. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01740479.

1 January 2025 in Journal of Cardiac Surgery
Verified
Journal Article
Open access
AMAhmad Makhdoum
Ahmad Makhdoum
MSMuhammad Suleman
Muhammad Suleman
BSBhavendra Singh
Bhavendra Singh
HAHatim Al-Raddadi
Hatim Al-Raddadi
LWLeah Wall
Leah Wall
TSTej Sheth
Tej Sheth
Background: The feasibility of valve‐in‐valve transcatheter aortic valve replacement (ViV‐TAVR) after surgical aortic valve replacement (SAVR) and the impact of aortic root enlargement (ARE) remain unclear. This study assesses the anatomical feasibility of Viv TAVR post‐SAVR, with and without ARE through detailed pre‐ and postoperative gated CT scans. Methods: We analyzed 62 patients undergoing SAVR ( n = 31) or SAVR + ARE ( n = 31) between September 2022 and May 2024. Pre‐ and postoperative gated CT scans were used to measure annular area, sinus of Valsalva (SOV) dimensions, coronary heights, and virtual valve‐to‐coronary (VTC) and valve‐to‐sinotubular junction (VTSTJ) distances. High‐risk ViV‐TAVR anatomy was defined as VTC < 4 mm or VTSTJ < 2 mm. Four enlargement techniques were used (Y‐Incision, Manouguian, Nicks and replacement of the coronary sinus). Results: Female patients were more prevalent in the SAVR + ARE group (61% vs. 19.4%, p < 0.001). Preoperatively and compared to the SAVR cohort, SAVR + ARE had a smaller annular area‐derived diameter (23 ± 2 mm vs. 26.8 ± 2.2 mm, p < 0.001) and SOV dimensions (28.8 ± 2 vs. 32.8 ± 3.6, p ≤ 0.001) and, both cohorts had coronary heights of ≥ 14 mm. Postoperatively, both groups had a significant reduction in coronary heights by at least 7–9 mm ( p < 0.001). On the contrary, the SOV dimension increased significantly by +3 mm in the SAVR + ARE group (< 0.001), while it decreased numerically in the SAVR‐only cohort (0.07). Similarly, the majority of both groups were considered low risk for future ViV TAVR (SAVR: 24/31, 74%) and (SAVR + ARE: 22/31, 71%), while 22.6% (7/31) of SAVR and 29% (9/31) of SAVR + ARE were considered anatomically high risk. Conclusion: While most patients who had SAVR, with or without ARE, were anatomically feasible for ViV TAVR, postoperative CT scans identified high‐risk anatomy in approximately 25% of cases. Pre‐ and post‐SAVR CT imaging offers insights into surgical planning and lifetime management of aortic valve disease.

24 January 2025 in JMIR Preprints
Verified
Preprint
Open access
JPJeremy Petch
Jeremy Petch
JBJuan Pablo Tabja Bortesi
Juan Pablo Tabja Bortesi
TSTej Sheth
Tej Sheth
MNMadhu Natarajan
Madhu Natarajan
NPNatalia Pinilla-Echeverri
Natalia Pinilla-Echeverri
JSJon-David Schwalm
Jon-David Schwalm
BACKGROUND Invasive coronary angiography (ICA) is the gold standard in the diagnosis of coronary artery disease (CAD). Being invasive, it carries rare but serious risks including myocardial infarction, stroke, major bleeding, and death. A large proportion of elective outpatients undergoing ICA have nonobstructive CAD, highlighting the suboptimal use of this test. Coronary computed tomographic angiography (CCTA) is a noninvasive option that provides similar information with less risk and is recommended as a first-line test for patients with low-to-intermediate risk of CAD. Leveraging artificial intelligence (AI) to appropriately direct patients to ICA or CCTA based on the predicted probability of disease may improve the efficiency and safety of diagnostic pathways. OBJECTIVE he CarDIA-AI (Coronary computed tomographic angiography to optimize the Diagnostic yield of Invasive Angiography for low-risk patients screened with Artificial Intelligence) study aims to evaluate whether AI-based risk assessment for obstructive CAD implemented within a centralized triage process can optimize the use of ICA in outpatients referred for nonurgent ICA. METHODS CarDIA-AI is a pragmatic, open-label, superior randomized controlled trial involving 2 Canadian cardiac centers. A total of 252 adults referred for elective outpatient ICA will be randomized 1:1 to usual care (directly proceeding to ICA) or to triage using an AI-based decision support tool. The AI-based decision support tool was developed using referral information from over 37,000 patients and uses a light gradient boosting machine model to predict the probability of obstructive CAD based on 42 clinically relevant predictors, including patient referral information, demographic characteristics, risk factors, and medical history. Participants in the intervention arm will have their ICA referral forms and medical charts reviewed, and select details entered into the decision support tool, which recommends CCTA or ICA based on the patient’s predicted probability of obstructive CAD. All patients will receive the selected imaging modality within 6 weeks of referral and will be subsequently followed for 90 days. The primary outcome is the proportion of normal or nonobstructive CAD diagnosed via ICA and will be assessed using a 2-sided z test to compare the patients referred for cardiac investigation with normal or nonobstructive CAD diagnosed through ICA between the intervention and control groups. Secondary outcomes include the number of angiograms avoided and the diagnostic yield of ICA. RESULTS Recruitment began on January 9, 2025, and is expected to conclude in mid to late 2025. As of April 14, 2025, we have enrolled 81 participants. Data analysis will begin once data collection is completed. We expect to submit the results for publication in 2026. CONCLUSIONS CarDIA-AI will be the first randomized controlled trial using AI to optimize patient selection for CCTA versus ICA, potentially improving diagnostic efficiency, avoiding unnecessary complications of ICA, and improving health care resource usage. CLINICALTRIAL ClinicalTrials.gov NCT06648239; https://clinicaltrials.gov/study/NCT06648239/ INTERNATIONAL REGISTERED REPORT DERR1-10.2196/71726

25 June 2026 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
TSTej Sheth
Tej Sheth
JRJosep Rodés-Cabau
Josep Rodés-Cabau
KPKarl Poon
Karl Poon
JPJean-Michel Paradis
Jean-Michel Paradis
NFNeil Fam
Neil Fam
MSMuhammad Suleman
Muhammad Suleman
BACKGROUND: This study evaluated the ability of the ABC Bicuspid Sizing Algorithm to predict aortic root rupture in patients treated with transcatheter aortic valve replacement using SAPIEN 3 valves. METHODS: We conducted a retrospective multicenter study among 15 centers in 7 countries of aortic root rupture cases and controls without root complications. Computed tomography analysis was performed blinded to rupture status. The ABC algorithm was applied to classify risk (high-risk criteria): (1) annular oversizing >10%, (2) intercommissural distance − valve diameter ≤1 mm, (3) maximum sinus diameter − valve diameter 1000 mm 3 and raphe + contralateral or ipsilateral leaflet calcium volume >800 mm 3 , (5) protruding nodular intercommissural distance calcium or full-length calcification of both leaflet edges. RESULTS: A total of 170 patients were included (23 ruptures and 147 controls). Cases exhibited higher total calcium volume (median: 1498 mm 3 versus 826 mm 3 ; P <0.001), smaller intercommissural distance difference (median: −0.15 versus 1.19 mm; P =0.009), smaller maximum sinus difference (median: 6.79 versus 9.19 mm; P <0.001), and greater annular oversizing (median: 6.57% versus 3.51%; P =0.047). The presence of any high-risk criterion had a sensitivity of 100% (95% CI, 85.7%–100%) and a specificity of 89.1% (95% CI, 83.1%–93.2%) for the identification of rupture cases. The diagnostic odds ratio was 374.5 (95% CI, 21.7–6459.9), with a positive likelihood ratio of 9.19 and a negative likelihood ratio of 0.023. CONCLUSIONS: High calcium volume, narrow sinus dimensions, and excessive valve oversizing were associated with aortic root rupture. The ABC algorithm showed promising performance for risk stratification of patients with bicuspid anatomy being considered for treatment with a SAPIEN 3 valve.